What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Canine Protein-Losing Enteropathy: Diagnosis and Management

At a Glance

Protein-losing enteropathy (PLE) in dogs is a syndrome of excessive plasma protein loss into the gastrointestinal tract, producing hypoalbuminemia and panhypoproteinemia. The condition results from disorders that disrupt intestinal mucosal integrity or lymphatic drainage, most commonly intestinal lymphangiectasia, inflammatory bowel disease (IBD), and fungal infections. Diagnosis requires systematic laboratory testing, imaging, and histopathology. Management targets dietary modification, immunosuppression when indicated, and anticoagulation for thromboembolic risk. Prognosis varies by underlying cause and response to therapy.

Diagnostic Component	Key Findings	Clinical Significance
Serum biochemistry	Hypoalbuminemia, panhypoproteinemia, hypocholesterolemia	Confirms protein loss, rule out protein-losing nephropathy and hepatic insufficiency
Fecal alpha-1 protease inhibitor	Elevated fecal alpha-1-PI concentration	Noninvasive confirmation of gastrointestinal protein loss
Abdominal ultrasound	Intestinal wall thickening, dilated lacteals, hyperechoic mucosa	Identifies structural abnormalities, guides biopsy site selection
Endoscopic biopsy	Dilated lymphatics, lymphoplasmacytic or eosinophilic inflammation	Definitive diagnosis of lymphangiectasia and IBD
Histopathology	Lacteal dilation, villous blunting, crypt hyperplasia	Differentiates primary from secondary lymphangiectasia

Pathophysiology of Protein-Losing Enteropathy

Protein-losing enteropathy results from disruption of the gastrointestinal mucosal barrier or obstruction of lymphatic drainage. Protein loss into the intestinal lumen exceeds hepatic synthetic capacity, producing hypoalbuminemia and decreased total protein concentration. Albumin, globulins, and other plasma proteins are lost indiscriminately, causing panhypoproteinemia. The Merck Veterinary Manual provides background on gastrointestinal disorders in dogs.

Intestinal Lymphangiectasia

Intestinal lymphangiectasia is characterized by dilation of lymphatic vessels within the intestinal wall, as described in a 2022 comparative review in Animals. This dilation allows protein-rich lymph to leak into the intestinal lumen. Primary lymphangiectasia is a congenital disorder of lymphatic development, while secondary lymphangiectasia results from conditions that obstruct lymphatic flow, such as right-sided heart failure, neoplasia, or granulomatous disease. A 2025 case report in the Open Veterinary Journal described a 10-month-old Border collie with persistent diarrhea, weight loss, steatorrhea, and limb edema. Abdominal ultrasound revealed intestinal wall thickening and signs indicative of lymphangiectasia. Strain elastography showed changes in intestinal rigidity parameters. After upper digestive endoscopy and histopathological examination, the dog was diagnosed with intestinal lymphangiectasia.

Inflammatory Bowel Disease

Chronic enteropathy, including IBD, can cause PLE through mucosal inflammation that increases permeability to proteins. A 2016 review in the Journal of Small Animal Practice discusses the relationship between IBD and chronic enteropathy in dogs. Lymphoplasmacytic or eosinophilic inflammation disrupts tight junctions between enterocytes, allowing protein leakage. The severity of protein loss correlates with the extent and intensity of mucosal inflammation. A 2023 case report in Ankara Üniversitesi Veteriner Fakültesi Dergisi described a 2-year-old American Staffordshire Terrier with progressive diarrhea for more than 3 months. Clinical findings, laboratory results, and ultrasound images were compatible with IBD and lymphangiectasia. Histopathological evaluation of punch biopsy samples confirmed both conditions.

Fungal and Infectious Causes

Fungal infections such as histoplasmosis can cause granulomatous inflammation in the intestinal wall, leading to PLE. Other infectious agents, including Tritrichomonas foetus, have been reported in dogs receiving immunosuppressive therapy for PLE. A 2020 case report in Veterinary Parasitology: Regional Studies and Reports described an 8-year-old spayed female Rottweiler under immunosuppressant treatment for PLE and intestinal lymphangiectasia that presented with anorexia, poor general condition, and diarrhea. A subcutaneous mass between the caudal abdominal mammary glands was found. Fine-needle aspiration cytology revealed inflammatory cells mixed with flagellated protozoan trophozoites belonging to Trichomonadida order. Final diagnosis of Tritrichomonas foetus infection was achieved with molecular analysis. This represents the first case of T. foetus infection described in a location different from the gastrointestinal tract in a dog.

Diagnostic Workup

The diagnostic approach to PLE requires confirmation of gastrointestinal protein loss, identification of the underlying cause, and exclusion of other causes of hypoalbuminemia such as protein-losing nephropathy and hepatic insufficiency.

Laboratory Assessment

Initial laboratory evaluation includes a complete blood count, serum biochemistry profile, and urinalysis. Hypoalbuminemia with concurrent hypoglobulinemia suggests gastrointestinal loss instead of hepatic or renal causes. Serum cholesterol is often decreased in lymphangiectasia due to impaired chylomicron absorption. A 2003 review in the Veterinary Clinics of North America: Small Animal Practice outlines the diagnostic approach to protein-losing enteropathies.

Fecal alpha-1 protease inhibitor (alpha-1-PI) concentration is a noninvasive test that confirms gastrointestinal protein loss. An enzyme-linked immunosorbent assay for canine alpha-1-PI was described in a 1998 issue of the American Journal of Veterinary Research. This test measures a protein that is lost into the intestinal lumen and resists degradation, providing a reliable marker of enteric protein loss. A 2000 review in Revue De Medecine Veterinaire discussed updates on noninvasive monitoring of intestinal disease in dogs and cats.

Imaging Studies

Abdominal ultrasound is essential for evaluating intestinal wall thickness, layering, and the presence of dilated lacteals. A 2025 case report in the Open Veterinary Journal described ultrasonographic findings in a dog with intestinal lymphangiectasia, including intestinal wall thickening and changes in rigidity parameters on strain elastography. The report demonstrated elastography's potential as a diagnostic and monitoring tool. Ultrasound also helps identify concurrent conditions such as abdominal effusion, mesenteric lymphadenopathy, or mass lesions.

Endoscopic Evaluation and Biopsy

Upper gastrointestinal endoscopy allows direct visualization of the duodenal mucosa and collection of biopsy samples. Endoscopic findings in lymphangiectasia include white, dilated lacteals on the mucosal surface, often described as white spots or dilated villi. A 2016 case report in Clínica Veterinária described endoscopic biopsy as the definitive diagnostic method for lymphangiectasia in a 7-year-old male Yorkshire Terrier with a 30-day history of diarrhea and ascites. Laboratory tests disclosed hypoproteinemia and hypoalbuminemia.

Histopathologic examination of biopsy specimens is required for definitive diagnosis. Findings include dilated lymphatic vessels within the villi and lamina propria, villous blunting, and crypt hyperplasia. Inflammatory cell infiltration, typically lymphoplasmacytic or eosinophilic, indicates concurrent IBD.

Differential Diagnoses

Other causes of hypoalbuminemia must be excluded before confirming PLE. Protein-losing nephropathy is identified by persistent proteinuria on urinalysis and urine protein-to-creatinine ratio. Hepatic insufficiency is evaluated through serum bile acids, albumin, and liver function tests. Cutaneous protein loss from severe burns or exudative skin disease is usually apparent on physical examination.

Management Strategies

Management of PLE targets the underlying cause while addressing complications such as hypoalbuminemia, edema, and thromboembolic risk. Treatment typically combines dietary modification, immunosuppressive therapy, and supportive care.

Dietary Modification

Dietary management is central to treating PLE, particularly in cases of intestinal lymphangiectasia. A low-fat diet reduces lymphatic flow and pressure within dilated lacteals, decreasing protein loss. Highly digestible protein sources support nitrogen balance and albumin synthesis. Medium-chain triglycerides can be used as an alternative energy source because they are absorbed directly into the portal circulation instead of through lymphatics.

A 2016 case report in Clínica Veterinária documented that a dog with lymphangiectasia remained free of clinical signs post-treatment when maintained on a fat-restricted diet. The 2025 Open Veterinary Journal case report described treatment with a low-fat diet and immunosuppressive drugs, which resulted in clinical and laboratory improvement and a reduction in the hardness rate on elastography. Dietary compliance is critical for long-term management, and owners must understand the importance of avoiding high-fat treats and table scraps.

Immunosuppressive Therapy

Immunosuppressive drugs are indicated when IBD is the underlying cause of PLE or when lymphangiectasia is associated with significant inflammation. Corticosteroids such as prednisolone are first-line agents. A 2013 study in the Journal of the American Veterinary Medical Association compared a chlorambucil-prednisolone combination with an azathioprine-prednisolone combination for treatment of chronic enteropathy with concurrent PLE in 27 dogs.

For dogs that do not respond adequately to corticosteroids alone, additional immunosuppressive agents such as cyclosporine or mycophenolate mofetil may be considered. The choice of immunosuppressive therapy depends on the severity of disease, presence of adverse effects, and individual patient response.

Anticoagulation

Dogs with PLE are at increased risk of thromboembolism due to loss of antithrombin III and other anticoagulant proteins into the gastrointestinal tract. Thromboembolic events can affect the pulmonary circulation, causing acute respiratory distress, or other vascular beds. Anticoagulant therapy with low-dose aspirin or clopidogrel may be considered to reduce thromboembolic risk, although evidence for specific protocols is limited.

Novel Therapeutic Approaches

Octreotide, a somatostatin analog, has been investigated for treatment of PLE in dogs. A 2024 retrospective study in the Journal of Veterinary Internal Medicine examined the use of octreotide for treatment of PLE in 18 dogs. A 2023 case report in Ankara Üniversitesi Veteriner Fakültesi Dergisi described successful management of IBD and lymphangiectasia in a dog using a combination of octreotide (10 µg/dog per day, BID, sc.) and tranexamic acid (10 mg/kg, BID, im.). Fecal consistency and defecation frequency returned to normal on day 15. At the end of the first month, hypoalbuminemia began to normalize, ascites completely disappeared, the thickness of the lamina muscularis layer began to normalize, and the patient began to gain weight. At the end of the second month, clinical signs and all laboratory results improved. The authors suggested that this combination can be used effectively and without side effects for treatment of IBD in dogs.

Tranexamic acid, an antifibrinolytic agent, may reduce protein loss by stabilizing the mucosal barrier and reducing fibrinolysis at sites of inflammation. These therapies represent emerging options for dogs that do not respond to conventional treatment.

Monitoring and Prognosis

Regular monitoring is essential to assess response to therapy and detect complications. Serum albumin and total protein concentrations should be measured every two to four weeks during initial treatment, then every one to three months once stabilized. Fecal alpha-1-PI concentration can be monitored to assess ongoing protein loss.

Clinical Assessment

Physical examination should evaluate body condition score, presence of edema or ascites, and gastrointestinal signs such as diarrhea, vomiting, and appetite. Weight monitoring provides an objective measure of response to therapy. Owners should be instructed to report any recurrence of diarrhea, vomiting, or edema.

Prognostic Factors

A 2007 study in the Journal of Veterinary Internal Medicine evaluated risk factors for negative outcome in dogs with chronic enteropathies. Factors associated with poorer prognosis include severe hypoalbuminemia at presentation, lack of response to dietary modification alone, and requirement for multiple immunosuppressive agents. Dogs with primary lymphangiectasia may have a more guarded long-term prognosis compared to those with secondary lymphangiectasia that resolves with treatment of the underlying cause.

Complications

Thromboembolism is a life-threatening complication of PLE. Clinical signs include acute dyspnea, tachypnea, and collapse. Dogs with severe hypoalbuminemia or concurrent hypercoagulable states are at highest risk. Other complications include bacterial translocation from the damaged intestinal mucosa, leading to sepsis, and malnutrition from chronic protein loss and malabsorption.

Common Failure Patterns

Treatment failure in PLE often results from incomplete diagnostic workup, inadequate dietary restriction, or insufficient immunosuppression. Dogs that fail to respond to initial therapy require reassessment of the underlying diagnosis and consideration of alternative or additional treatments.

Diagnostic Errors

Failure to identify the specific cause of PLE can lead to inappropriate treatment. For example, treating lymphangiectasia with immunosuppressive therapy alone without dietary modification will not address the underlying lymphatic obstruction. Similarly, failing to diagnose concurrent IBD may result in inadequate immunosuppression.

Dietary Noncompliance

Dietary indiscretion is a common cause of relapse in dogs with PLE. Owners may inadvertently feed high-fat treats or allow access to other pets' food. Strict dietary counseling and regular reinforcement of dietary restrictions are necessary for long-term management.

Inadequate Immunosuppression

Some dogs require higher doses or additional immunosuppressive agents to achieve remission. A 2013 study in the Journal of the American Veterinary Medical Association demonstrated that combination therapy with chlorambucil and prednisolone may be more effective than azathioprine and prednisolone in some cases. Dogs that do not respond to prednisolone alone may benefit from addition of a second immunosuppressive agent.

Professional Escalation Criteria

Veterinarians should consider referral to a veterinary internal medicine specialist when:

Serum albumin remains below 1.5 g/dL despite four weeks of appropriate therapy
Clinical signs such as diarrhea, vomiting, or edema worsen or fail to improve
Thromboembolic complications develop or are suspected
The dog requires multiple immunosuppressive agents or novel therapies such as octreotide
Diagnostic uncertainty persists after initial workup
The dog experiences adverse effects from immunosuppressive therapy

Emergency referral is indicated for dogs with acute respiratory distress suggestive of pulmonary thromboembolism, severe dehydration, or suspected sepsis.

Practical Decision Framework for Selecting and Adjusting PLE Therapy

Managing canine protein-losing enteropathy requires a structured approach to therapy selection, monitoring, and adjustment because individual patient responses vary widely. A systematic decision framework helps veterinarians match treatment intensity to disease severity, track objective endpoints, and recognize when to escalate or change therapy. This section provides a practical framework based on published evidence and clinical reasoning, with specific record-keeping recommendations and troubleshooting methods.

Severity Stratification at Presentation

Before selecting therapy, classify the patient into one of three severity categories based on serum albumin concentration, clinical signs, and thromboembolic risk. This stratification guides initial treatment intensity and monitoring frequency.

Mild PLE: Serum albumin 2.0 to 2.5 g/dL with mild gastrointestinal signs such as intermittent diarrhea or soft stool, no edema or ascites, and body condition score greater than 4 out of 9. These dogs often respond to dietary modification alone or with minimal immunosuppression.

Moderate PLE: Serum albumin 1.5 to 2.0 g/dL with persistent diarrhea, weight loss, and mild to moderate edema or ascites. These patients typically require dietary modification plus immunosuppressive therapy.

Initial Therapy Selection Algorithm

For dogs with mild PLE, implement dietary modification alone for two to four weeks. If serum albumin improves by at least 0.3 g/dL and clinical signs resolve, continue dietary management alone. If no improvement occurs, add immunosuppressive therapy.

Record System for Tracking Response

Maintain a standardized record for each PLE patient to track objective parameters over time. The following table provides a template for monitoring at each recheck visit.

Parameter	Baseline	Week 2	Week 4	Week 8	Week 12	Notes
Serum albumin (g/dL)						Target >2.5
Total protein (g/dL)
Body weight (kg)
Body condition score (1-9)
Fecal consistency score (1-5)						1=formed, 5=watery
Edema/ascites (0-3)						0=none, 3=severe
Medication doses						Record all drugs
Adverse effects

Record fecal consistency using a standardized scoring system such as the Purina Fecal Scoring System or a clinic-specific scale. Document the presence and severity of edema by location such as limbs, ventral abdomen, or face, and ascites by abdominal distension and fluid wave on palpation.

Troubleshooting Methods for Common Scenarios

Scenario 1: Serum albumin fails to improve after four weeks of dietary modification alone.

Reassess dietary compliance. Owners may inadvertently feed high-fat treats or allow access to other pets' food. Review the diet history in detail, including all treats, table scraps, and medications that may contain fat. If compliance is adequate, consider adding immunosuppressive therapy. Perform repeat abdominal ultrasound to evaluate for progression of intestinal wall thickening or development of new lesions. Consider repeat fecal alpha-1-PI testing to confirm ongoing protein loss.

Scenario 2: Serum albumin improves initially but then plateaus or declines.

Evaluate for dietary indiscretion or changes in medication administration. Check for development of concurrent disease such as pancreatitis, hepatic insufficiency, or protein-losing nephropathy. Perform urinalysis with protein-to-creatinine ratio to rule out protein-losing nephropathy. Consider repeat abdominal ultrasound and endoscopic biopsy if the initial diagnosis was not confirmed histopathologically. A 2020 case report in Veterinary Parasitology: Regional Studies and Reports described a dog under immunosuppressant treatment for PLE and intestinal lymphangiectasia that developed Tritrichomonas foetus infection, highlighting the importance of considering infectious complications in immunosuppressed patients.

Scenario 3: Clinical signs improve but hypoalbuminemia persists.

Some dogs maintain adequate clinical function despite persistent mild hypoalbuminemia. If serum albumin remains above 2.0 g/dL and the dog has no edema, ascites, or diarrhea, continue current therapy and monitor monthly. If albumin falls below 2.0 g/dL or clinical signs recur, escalate therapy. Consider adding a second immunosuppressive agent or octreotide.

Scenario 4: Dog develops acute dyspnea or collapse.

Suspect pulmonary thromboembolism. This is a medical emergency requiring immediate referral. Dogs with PLE lose antithrombin III and other anticoagulant proteins into the gastrointestinal tract, creating a hypercoagulable state. Perform thoracic radiographs, pulse oximetry, and arterial blood gas analysis if available. Administer supplemental oxygen and consider anticoagulation with heparin. Refer to an emergency facility for advanced diagnostic imaging and management.

Scenario 5: Dog develops severe diarrhea or vomiting during immunosuppressive therapy.

Consider infectious complications such as bacterial overgrowth, parasitic infection, or fungal disease. Perform fecal flotation, direct smear, and Giardia antigen testing. Consider fecal culture and sensitivity if bacterial enteritis is suspected. A 2020 case report in Veterinary Parasitology: Regional Studies and Reports described T. foetus infection in a dog receiving immunosuppressant therapy for PLE. Reduce immunosuppressive doses temporarily if infection is confirmed and treat the underlying infection. Once infection resolves, gradually reintroduce immunosuppression as needed.

Comparison of Immunosuppressive Protocols

The choice of immunosuppressive protocol depends on disease severity, patient tolerance, and clinician experience. The following comparison summarizes key differences between commonly used protocols.

Prednisolone alone: First-line therapy for moderate PLE. Advantages include low cost, oral administration, and extensive clinical experience. Disadvantages include potential for adverse effects such as polyuria, polydipsia, panting, and increased risk of infection. Some dogs develop steroid resistance over time.

Prednisolone plus chlorambucil: A 2013 study in the Journal of the American Veterinary Medical Association compared this combination with prednisolone plus azathioprine in 27 dogs with chronic enteropathy and concurrent PLE. Chlorambucil is an alkylating agent with a relatively favorable safety profile. Advantages include potential for steroid-sparing effects and efficacy in refractory cases. Disadvantages include bone marrow suppression requiring regular monitoring of complete blood counts.

Prednisolone plus azathioprine: This combination is commonly used for IBD-associated PLE. Azathioprine is a purine analog that inhibits lymphocyte proliferation. Advantages include established efficacy in IBD. Disadvantages include delayed onset of action of two to four weeks, potential for hepatotoxicity, and bone marrow suppression. Azathioprine should not be used in cats due to risk of severe myelosuppression.

Cyclosporine: A calcineurin inhibitor that suppresses T-cell activation. Advantages include rapid onset of action and efficacy in steroid-refractory cases. Disadvantages include high cost, need for therapeutic drug monitoring, and potential for gingival hyperplasia and gastrointestinal upset.

Mycophenolate mofetil: An inosine monophosphate dehydrogenase inhibitor that suppresses lymphocyte proliferation. Advantages include rapid onset and steroid-sparing effects. Disadvantages include gastrointestinal side effects such as diarrhea and vomiting, and high cost.

Octreotide and Tranexamic Acid Protocol

Octreotide is a somatostatin analog that reduces gastrointestinal secretions, decreases splanchnic blood flow, and reduces lymphatic flow. Tranexamic acid is an antifibrinolytic agent that may reduce protein loss by stabilizing the mucosal barrier and reducing fibrinolysis at sites of inflammation.

When considering this protocol, document baseline serum albumin, total protein, fecal consistency score, and presence of edema or ascites. Administer octreotide subcutaneously at 10 µg per dog twice daily and tranexamic acid intramuscularly at 10 mg/kg twice daily. Monitor for adverse effects including gastrointestinal upset, injection site reactions, and changes in blood glucose. Recheck serum albumin and clinical signs at two weeks and four weeks. If no improvement occurs after four weeks, consider alternative therapies or referral to a veterinary internal medicine specialist.

When to Escalate Therapy

Escalate therapy when serum albumin fails to increase by at least 0.3 g/dL after four weeks of appropriate treatment, clinical signs such as diarrhea, vomiting, or edema worsen or fail to improve, the dog develops new complications such as thromboembolism or infection, or serum albumin falls below 1.5 g/dL despite therapy.

Escalation options include adding a second immunosuppressive agent, switching to a different immunosuppressive protocol, adding octreotide and tranexamic acid, or referring to a veterinary internal medicine specialist for advanced diagnostic evaluation and management.

When to Consider Referral

Referral to a veterinary internal medicine specialist is indicated when diagnostic uncertainty persists after initial workup including abdominal ultrasound and endoscopic biopsy, serum albumin remains below 1.5 g/dL despite four weeks of appropriate therapy, the dog requires multiple immunosuppressive agents or novel therapies such as octreotide, thromboembolic complications develop or are suspected, or the dog experiences adverse effects from immunosuppressive therapy that limit treatment options.

Emergency referral is indicated for dogs with acute respiratory distress suggestive of pulmonary thromboembolism, severe dehydration, or suspected sepsis.

Practical Implementation Steps for Clinicians

At initial presentation, classify PLE severity as mild, moderate, or severe based on serum albumin and clinical signs.
Begin dietary modification with a low-fat, highly digestible diet for all patients.
For mild PLE, monitor dietary response for two to four weeks before adding immunosuppression.
For moderate PLE, start prednisolone concurrently with dietary modification.
For severe PLE, start prednisolone plus a second immunosuppressive agent concurrently with dietary modification.
Create a standardized record for each patient using the monitoring table provided.
Recheck serum albumin, total protein, body weight, and clinical signs every two weeks during initial treatment.
If albumin improves by at least 0.3 g/dL at four weeks, continue current therapy and extend recheck intervals to monthly.
If albumin fails to improve or declines, escalate therapy or consider referral.
Monitor complete blood counts monthly for dogs receiving chlorambucil or azathioprine to detect bone marrow suppression.
Educate owners about dietary compliance, medication administration, and signs of complications such as thromboembolism or infection.
Document all treatment changes and patient responses in the medical record for ongoing management and future reference.

Practical Decision Framework for Selecting and Adjusting PLE Therapy

Severity Stratification at Presentation

Severe PLE: Serum albumin below 1.5 g/dL with marked edema, ascites, pleural effusion, or signs of thromboembolism. These dogs need aggressive therapy including dietary modification, immunosuppression, anticoagulation, and potentially novel therapies such as octreotide. A 2007 study in the Journal of Veterinary Internal Medicine identified severe hypoalbuminemia as a risk factor for negative outcome in dogs with chronic enteropathies (source: PubMed bibliographic record for Chronic enteropathies in dogs: evaluation of risk factors for negative outcome, Journal of Veterinary Internal Medicine, 2007, https://pubmed.ncbi.nlm.nih.gov/17708389).

Initial Therapy Selection Algorithm

For all PLE patients, begin with dietary modification using a low-fat, highly digestible diet. A 2016 case report in Clínica Veterinária documented that a dog with lymphangiectasia remained free of clinical signs post-treatment when maintained on a fat-restricted diet (source: Semantic Scholar record for Intestinal lymphangiectasia in a dog - case report, Clínica Veterinária, 2016, https://doi.org/10.46958/rcv.2016.xxi.n.124.p.98-104). The 2025 Open Veterinary Journal case report described treatment with a low-fat diet and immunosuppressive drugs, which resulted in clinical and laboratory improvement (source: Semantic Scholar record for Intestinal lymphangiectasia in a dog: Clinical, ultrasonographic, endoscopic, and strain elastographic aspects, Open Veterinary Journal, 2025, https://doi.org/10.5455/OVJ.2025.v15.i2.54).

For dogs with moderate PLE, start dietary modification and prednisolone at 1 to 2 mg/kg orally once daily. A 2013 study in the Journal of the American Veterinary Medical Association compared a chlorambucil-prednisolone combination with an azathioprine-prednisolone combination for treatment of chronic enteropathy with concurrent PLE in 27 dogs (source: PubMed bibliographic record for Comparison of a chlorambucil-prednisolone combination with an azathioprine-prednisolone combination for treatment of chronic enteropathy with concurrent protein-losing enteropathy in dogs: 27 cases (2007-2010), Journal of the American Veterinary Medical Association, 2013, https://pubmed.ncbi.nlm.nih.gov/23725434). For dogs that do not respond to prednisolone alone within two to four weeks, consider adding a second immunosuppressive agent such as chlorambucil, azathioprine, cyclosporine, or mycophenolate mofetil.

For dogs with severe PLE, begin dietary modification, prednisolone, and a second immunosuppressive agent concurrently. Consider anticoagulation with low-dose aspirin or clopidogrel for thromboembolic prophylaxis. For dogs with refractory disease, octreotide may be considered. A 2024 retrospective study in the Journal of Veterinary Internal Medicine examined the use of octreotide for treatment of PLE in 18 dogs (source: PubMed bibliographic record for Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases, Journal of Veterinary Internal Medicine, 2024, https://pubmed.ncbi.nlm.nih.gov/38038236). A 2023 case report in Ankara Üniversitesi Veteriner Fakültesi Dergisi described successful management of IBD and lymphangiectasia in a dog using a combination of octreotide (10 µg/dog per day, BID, sc.) and tranexamic acid (10 mg/kg, BID, im.) (source: Semantic Scholar record for Management of inflammatory bowel disease and lymphangiectasia in a dog with octreotide and tranexamic acid, Ankara Üniversitesi Veteriner Fakültesi Dergisi, 2023, https://doi.org/10.33988/auvfd.1263493).

Record System for Tracking Response

Maintain a standardized record for each PLE patient to track objective parameters over time. The following table provides a template for monitoring at each recheck visit.

Parameter	Baseline	Week 2	Week 4	Week 8	Week 12	Notes
Serum albumin (g/dL)						Target >2.5
Total protein (g/dL)
Body weight (kg)
Body condition score (1-9)
Fecal consistency score (1-5)						1=formed, 5=watery
Edema/ascites (0-3)						0=none, 3=severe
Medication doses						Record all drugs
Adverse effects

Troubleshooting Methods for Common Scenarios

Scenario 1: Serum albumin fails to improve after four weeks of dietary modification alone.

Scenario 2: Serum albumin improves initially but then plateaus or declines.

Scenario 3: Clinical signs improve but hypoalbuminemia persists.

Scenario 4: Dog develops acute dyspnea or collapse.

Scenario 5: Dog develops severe diarrhea or vomiting during immunosuppressive therapy.

Consider infectious complications such as bacterial overgrowth, parasitic infection, or fungal disease. Perform fecal flotation, direct smear, and Giardia antigen testing. Consider fecal culture and sensitivity if bacterial enteritis is suspected. A 2020 case report in Veterinary Parasitology: Regional Studies and Reports described T. foetus infection in a dog receiving immunosuppressant therapy for PLE (source: Semantic Scholar record for A case of misplaced Tritrichomonas foetus infection in a dog in Northern Italy, Veterinary Parasitology: Regional Studies and Reports, 2020, https://doi.org/10.1016/j.vprsr.2020.100451). Reduce immunosuppressive doses temporarily if infection is confirmed and treat the underlying infection. Once infection resolves, gradually reintroduce immunosuppression as needed.

Comparison of Immunosuppressive Protocols

The choice of immunosuppressive protocol depends on disease severity, patient tolerance, and clinician experience. The following comparison summarizes key differences between commonly used protocols.

Prednisolone plus chlorambucil: A 2013 study in the Journal of the American Veterinary Medical Association compared this combination with prednisolone plus azathioprine in 27 dogs with chronic enteropathy and concurrent PLE (source: PubMed bibliographic record for Comparison of a chlorambucil-prednisolone combination with an azathioprine-prednisolone combination for treatment of chronic enteropathy with concurrent protein-losing enteropathy in dogs: 27 cases (2007-2010), Journal of the American Veterinary Medical Association, 2013, https://pubmed.ncbi.nlm.nih.gov/23725434). Chlorambucil is an alkylating agent with a relatively favorable safety profile. Advantages include potential for steroid-sparing effects and efficacy in refractory cases. Disadvantages include bone marrow suppression requiring regular monitoring of complete blood counts.

Octreotide and Tranexamic Acid Protocol

For dogs with refractory PLE that do not respond to conventional immunosuppressive therapy, octreotide and tranexamic acid represent emerging therapeutic options. A 2024 retrospective study in the Journal of Veterinary Internal Medicine examined the use of octreotide for treatment of PLE in 18 dogs (source: PubMed bibliographic record for Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases, Journal of Veterinary Internal Medicine, 2024, https://pubmed.ncbi.nlm.nih.gov/38038236). A 2023 case report in Ankara Üniversitesi Veteriner Fakültesi Dergisi described successful management of IBD and lymphangiectasia in a dog using a combination of octreotide (10 µg/dog per day, BID, sc.) and tranexamic acid (10 mg/kg, BID, im.) (source: Semantic Scholar record for Management of inflammatory bowel disease and lymphangiectasia in a dog with octreotide and tranexamic acid, Ankara Üniversitesi Veteriner Fakültesi Dergisi, 2023, https://doi.org/10.33988/auvfd.1263493).

When to Escalate Therapy

When to Consider Referral

Emergency referral is indicated for dogs with acute respiratory distress suggestive of pulmonary thromboembolism, severe dehydration, or suspected sepsis.

Practical Implementation Steps for Clinicians

At initial presentation, classify PLE severity as mild, moderate, or severe based on serum albumin and clinical signs.
Begin dietary modification with a low-fat, highly digestible diet for all patients.
For mild PLE, monitor dietary response for two to four weeks before adding immunosuppression.
For moderate PLE, start prednisolone concurrently with dietary modification.
For severe PLE, start prednisolone plus a second immunosuppressive agent concurrently with dietary modification.
Create a standardized record for each patient using the monitoring table provided.
Recheck serum albumin, total protein, body weight, and clinical signs every two weeks during initial treatment.
If albumin improves by at least 0.3 g/dL at four weeks, continue current therapy and extend recheck intervals to monthly.
If albumin fails to improve or declines, escalate therapy or consider referral.
Monitor complete blood counts monthly for dogs receiving chlorambucil or azathioprine to detect bone marrow suppression.
Educate owners about dietary compliance, medication administration, and signs of complications such as thromboembolism or infection.
Document all treatment changes and patient responses in the medical record for ongoing management and future reference.

Frequently Asked Questions

What is the difference between protein-losing enteropathy and protein-losing nephropathy?

Protein-losing enteropathy involves loss of proteins through the gastrointestinal tract, while protein-losing nephropathy involves loss through the kidneys. PLE typically causes panhypoproteinemia with decreased albumin and globulins, whereas protein-losing nephropathy primarily causes hypoalbuminemia with normal or increased globulins. Urinalysis with protein-to-creatinine ratio helps differentiate these conditions.

How is intestinal lymphangiectasia diagnosed definitively?

Definitive diagnosis of intestinal lymphangiectasia requires histopathologic examination of intestinal biopsy specimens obtained via endoscopy or surgery. Endoscopic findings of dilated lacteals on the mucosal surface are highly suggestive, but biopsy confirmation is necessary. A 2025 case report in the Open Veterinary Journal described the use of strain elastography as a diagnostic and monitoring tool for lymphangiectasia, demonstrating changes in intestinal rigidity parameters that improved with treatment.

Can protein-losing enteropathy be cured?

The potential for cure depends on the underlying cause. Secondary lymphangiectasia caused by conditions such as right-sided heart failure or neoplasia may resolve with treatment of the primary disease. Primary lymphangiectasia and IBD-associated PLE are typically managed long-term instead of cured, with dietary modification and immunosuppressive therapy controlling clinical signs.

What dietary changes are most important for dogs with PLE?

A low-fat, highly digestible diet is the cornerstone of dietary management for PLE, particularly in lymphangiectasia. Fat restriction reduces lymphatic flow and pressure within dilated lacteals. Medium-chain triglycerides can be used as an alternative energy source. Dietary compliance must be strict, avoiding all high-fat treats and table scraps.

What is the role of octreotide in treating PLE?

Octreotide is a somatostatin analog that reduces gastrointestinal secretions and lymphatic flow. A 2024 retrospective study in the Journal of Veterinary Internal Medicine examined its use in 18 dogs with PLE. A 2023 case report described successful use of octreotide combined with tranexamic acid in a dog with IBD and lymphangiectasia, with improvement in clinical signs and laboratory parameters within one month.

Why do dogs with PLE develop thromboembolism?

Dogs with PLE lose antithrombin III and other anticoagulant proteins into the gastrointestinal tract, creating a hypercoagulable state. This increases the risk of thromboembolism, particularly pulmonary thromboembolism. Anticoagulant therapy may be considered to reduce this risk, although specific protocols require individual patient assessment.

How often should a dog with PLE be monitored?

Monitoring frequency depends on disease severity and response to therapy. During initial treatment, serum albumin and total protein should be measured every two to four weeks. Once stabilized, monitoring every one to three months is appropriate. Clinical assessment including body weight, body condition score, and presence of edema should be performed at each visit.

What is the prognosis for dogs with PLE?

Prognosis varies widely depending on the underlying cause and response to therapy. Dogs with mild to moderate disease that respond to dietary modification and immunosuppression may have a good long-term outcome. Factors associated with poorer prognosis include severe hypoalbuminemia at presentation, lack of response to dietary therapy alone, and requirement for multiple immunosuppressive agents, as reported in a 2007 study in the Journal of Veterinary Internal Medicine.

Related Veterinary Guides

References and Further Reading

www.merckvetmanual.com
www.aaha.org
www.acvim.org
Merck Veterinary Manual. Merck Veterinary Manual.
Animal Health and Welfare. World Organisation for Animal Health.
Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases.. Journal of veterinary internal medicine, 2024.
Pathophysiology, Diagnosis, and Management of Canine Intestinal Lymphangiectasia: A Comparative Review.. Animals : an open access journal from MDPI, 2022.
Comparison of a chlorambucil-prednisolone combination with an azathioprine-prednisolone combination for treatment of chronic enteropathy with concurrent protein-losing enteropathy in dogs: 27 cases (2007-2010).. Journal of the American Veterinary Medical Association, 2013.
Inflammatory bowel disease versus chronic enteropathy in dogs: are they one and the same?. The Journal of small animal practice, 2016.
Chronic enteropathies in dogs: evaluation of risk factors for negative outcome.. Journal of veterinary internal medicine, 2007.
Protein-losing enteropathies.. The Veterinary clinics of North America. Small animal practice, 2003.
Intestinal lymphangiectasia in a dog: Clinical, ultrasonographic, endoscopic, and strain elastographic aspects. Open Veterinary Journal, 2025.
Intestinal lymphangiectasia in a dog.. 2016.
Management of inflammatory bowel disease and lymphangiectasia in a dog with octreotide and tranexamic acid. Ankara Üniversitesi Veteriner Fakültesi Dergisi, 2023.
Intestinal lymphangiectasia in a dog - case report. Clínica Veterinária, 2016.
A case of "misplaced" Tritrichomonas foetus infection in a dog in Northern Italy.. Veterinary Parasitology: Regional Studies and Reports, 2020.
Enzyme-linked immunosorbent assay for canine α1-protease inhibitor. American Journal of Veterinary Research, 1998.
Update on the non-invasive monitoring of intestinal disease in dogs and cats. Revue De Medecine Veterinaire, 2000.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.